Attana, Karoliniska Universitetssjukhuset and KTH receives project grant of 4.8 MSEK
Stockholm, November 16th, 2017 – Attana AB, Karolinska Universitetssjukhuset and KTH, Royal Institute of Technology has been granted 4.8 MSEK from the Vinnova program supporting R&D of biological drugs. The grant is used for development of bispecific antibodies targeting leukemia and hematopetic stemcells.
The project aims at developing bispecific antibodies targeting stem cells and leukaemia cells. To optimise the antibodies Attana´s cell based biosensor combined with a newly developed immunological technology at KTH. This will provide information about contact dynamics and kinetics, immune synapse formation and apoptosis of target cells.
The ambitions of the project are both to develop a therapeutic antibody and a general process for efficient development of therapeutic antibodies prior to animal testing and clinical trials.
Attana receives 600.000 SEK of the grant directly from Vinnova. The remaining part of the grant is divided between Karolinska Universitetssjukhuset and KTH.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 70 15676765
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact email@example.com .